The Danish drugmaker said it had decided to terminate development of the first-in-class, oral glutamate mGluR4 positive allosteric modulator – which was Pexton’s only clinical-stage programme when it was bought in 2018 – after the drug missed all its objective in the phase 2 study..
Lundbeck drops Parkinson’s drug acquired ... - Cure Parkinson's
Lundbeck drops Parkinson’s drug acquired in €905m deal
Written by
Farooqji
To view profiles and participate in discussions please or .
Not what you're looking for?
You may also like...
Lundbeck bags a PhII Parkinson’s drug with $1.1B Prexton buyout deal
As per deal, Lundbeck is handing over $123 million and committing to about a billion dollars more...
Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2020
145 trials are registered and ongoing clinical trials for therapeutics targeting PD, of which 51...
Constipation in Parkinson’s disease
Parkinson,s disease for 14 years
Constipation for 12 years
Improvement now with Emma 1-2...
Mucuna pruriens in Parkinson’s
Mucuna pruriens in Parkinson’s disease: a double blind clinical and pharmacological study
R...
In whom the pill drops.
The more I look at this site, the more I see alternative / complimentary / etc. therapies.
Am I...
Cough medicine drug could stop Parkinson’s progression
Indian scientists develop new drug for Parkinson’s
Glucose dysregulation in Parkinson’s disease: 
